Novel glaucoma solution enters trials

Article

INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement from Inspire Pharmaceuticals Inc.

INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement made by Inspire Pharmaceuticals Inc.

The Rho kinase inhibitor interferes with the actin cytoskeleton of the trabecular meshwork to lower intraocular pressure (IOP).

This placebo-controlled dose-escalating trial will appraise the compound's safety, efficacy and tolerability in early stage glaucoma or ocular hypertension.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
A blue eye with a large splash of blue liquid coming out of it. Vitreoretinal surgery ILM dye stain concept. Image credit: ©Sergey Nivens – stock.adobe.com

Internal limiting membrane staining dye ILM-Blue from DORC (Zeiss) receives NMPA approval in China

Hattie Hayes
March 27th 2025
Article

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A person typing on a computer keyboard as icons representing documents and papers. Research paper publication concept image. Image credit: ©cherdchai – stock.adobe.com

Nanoscope Therapeutics publishes clinical results of MCO-010 findings for patients with retinitis pigmentosa

Martin David Harp
March 26th 2025
Article

The synthetic opsin was packaged into an optimised AAV2 gene therapy vector that targets human retinal bipolar cells.

European Union flags outside the European Commission, where the Alcon Clareon Vivity IOL received a CE mark. Image credit: ©Arcady – stock.adobe.com

Alcon Clareon Vivity IOL receives CE mark, European commercialisation announced

Hattie Hayes
March 25th 2025
Article

The lens will be available with the Monarch IV manual delivery system in Q2 and the AutonoMe Automated Pre-Loaded Delivery System in Q3

The Moorfields Eye Hospital NHS Foundation Trust logo courtesy NHS Foundation Trust. Insitro logo courtesy Insitro. Lock and data point assets created with Canva.

Moorfields Eye Hospital INSIGHT research hub will collaborate with artificial intelligence development company Insitro

Hattie Hayes
March 24th 2025
Article

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases

Two boxes, labeled "yes" and "no." There is a red checkmark in the "no" box. Concept portraying an ophthalmic clinical trial which does not meet its endpoint. Image credit: ©Matthew Benoit – stock.adobe.com

Phase 3 COAST trial fails to meet primary endpoints for wet AMD, Opthea reports

Martin David Harp
March 24th 2025
Article

The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration

© 2025 MJH Life Sciences

All rights reserved.